Economic spectroscopic evaluation of Cervical Cancer

Information

  • Research Project
  • 6830442
  • ApplicationId
    6830442
  • Core Project Number
    R44CA110149
  • Full Project Number
    1R44CA110149-01
  • Serial Number
    110149
  • FOA Number
    PAR-03-125
  • Sub Project Id
  • Project Start Date
    8/18/2004 - 20 years ago
  • Project End Date
    1/31/2005 - 19 years ago
  • Program Officer Name
    LIDDELL HUPPI, REBECCA
  • Budget Start Date
    8/18/2004 - 20 years ago
  • Budget End Date
    1/31/2005 - 19 years ago
  • Fiscal Year
    2004
  • Support Year
    1
  • Suffix
  • Award Notice Date
    8/18/2004 - 20 years ago

Economic spectroscopic evaluation of Cervical Cancer

DESCRIPTION (provided by applicant): Cervical Cancer is the second most common type of cancer in women worldwide and the leading cause of cancer related mortality in women in developing countries. Early detection and diagnosis can saves lives and reduce the burden on the national healthcare system. We have built a non-invasive research-prototype point-of-care device to detect early cancerous conditions of the uterine cervix. We have tested this prototype in a multi-center national study accruing data from 600 women for training our algorithm. Through conversations with the FDA we now have in place a pivotal trial protocol for validating our algorithm. We will use a pre-production version of our device in this pivotal study. The pre-production device will be a cost and size reduced, portable, rugged and user-friendlier device and is intended to be identical to the device intended for sale without incurring the tooling costs necessary to enter the production phase. In Phase I of this fast track application we will address the high-risk aspects of building this pre-production device as well as arrive at a conceptual design. In Phase II we will finalize this design (both component level and systems integration) and build ten copies of the device to support the pivotal trial. We will also complete necessary systems tests and determine inter/intra device variability. We will conclude with the design documentation necessary for our PMA submission.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R44
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    101625
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    394
  • Ed Inst. Type
  • Funding ICs
    NCI:101625\
  • Funding Mechanism
  • Study Section
    ZCA1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    GUIDED THERAPEUTICS
  • Organization Department
  • Organization DUNS
    800743106
  • Organization City
    NORCROSS
  • Organization State
    GA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    30092
  • Organization District
    UNITED STATES